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ABSTRACT 
The presence of fluorine can provide organic compounds with useful biological 
properties, such as increased metabolic stability and drug uptake. Because of these advantages, 
fluorinated compounds make up about 30% of the drug industry. However, fluorination of 
complex molecules is difficult due to fluorine’s high electronegativity. 
Fluorinated isoxazoles are of particular interest in the pharmaceutical industry. Isoxazoles 
are five-membered heterocycles with oxygen and nitrogen in the 1, 2 positions that are able to 
engage in interactions unavailable to other ring structures, conferring advantageous biological 
properties upon compounds containing them. However, there are limited synthetic routes for 
fluorinated isoxazoles, and those that have been reported in the past have poor yields and require 
harsh conditions.  
In 2014, a gold-catalyzed cyclization-fluorination of O-methyl oximes to produce 
fluorinated isoxazole was reported. The goal of this project was to test synthetic routes of 
fluorinated isoxazoles that require less expensive materials, focusing on the synthesis of 4-
fluoro-3,5-disubstituted isoxazole via a silver-catalyzed cyclization. 
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Chapter 1: Introduction & Background 
Section 1.1 – Fluorine in Medicinal Chemistry 
Characteristics of Fluorine 
Fluorine is becoming increasingly important in medicinal chemistry. Today, around 25% 
of pharmaceutical drugs in the United states contain fluorine, due to the number of unique 
properties fluorine possesses1.  
The Van der Waals radius of fluorine is 1.47 Å, similar to hydrogen’s, which is 1.20 Å 2. 
This allows fluorine to act as a substitute for hydrogen while causing minimal steric hindrance, 
making it a bioisostere of hydrogen2. Because the size and conformation of the molecule is 
preserved, the biological activity of the compound is retained2. This makes fluorine an important 
substitute in pharmaceutics, due to the number of hydrocarbons available in organic drug 
compounds2.  
Fluorine is the most electronegative atom, with a value of 3.98 on the Pauling 
Electronegativity Scale, compared to 2.20 for hydrogen, 2.55 for carbon, and 3.44 for oxygen2. 
This causes fluorine to change the pKa of nearby functional groups, which can alter the 
bioavailability, kinetics, and binding affinity of fluorinated compounds2. These alterations can 
then lead to changes in the toxicity, potency, and selectivity of the compound2. For example, 
adding fluorine to compounds containing basic polar amines can reduce the effects of the 
amine’s lone pairs due to its strong electron withdrawing properties2. Because overly basic and 
polar amines can decrease a drug’s ability to permeate cell membranes, adding fluorine can 
increase bioavailability, making the drug more effective2.    
Fluorine’s high electronegativity also affects its bonding capabilities with carbon. Bonds 
between carbon and fluorine are short in length and very stable with a bond energy of 116 
kcal/mol3. For comparison, carbon-hydrogen bond energy is 99 kcal/mol3. Because carbon-
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fluorine bonds have an increased oxidative and thermal stability, they cannot be metabolized as 
quickly as carbon-hydrogen bonds3. This decreased metabolism allows more time for drug 
uptake3. 
Bond Bond Length (Å) Bond Dissociation 
Energy (kcal/mol) 
C-H 1.09 99 
C-F 1.39 116 
C-OH 1.43 85 
Table 1. Physicochemical properties of the carbon-fluorine bond 
compared to other C-X bonds3 
Addition of fluorinated functional groups can either increase or decrease lipophilicity 
depending on the structure, and therefore affect the partitioning of a drug into membranes as well 
as hydrophobic interactions with specific binding sites3. For example, when fluorine replaces a 
hydrogen atom in a benzene molecule, lipophilicity is increased moderately, and when replaced 
with a trifluoromethyl group, it increases significantly3.  Increased lipophilicity leads to 
increased receptor activity in the lipid bilayer of the cell membrane, allowing for increased drug 
uptake3. If a drug is too hydrophilic, the drug will be readily absorbed at the small intestine but 
cannot be delivered to the cell3. If a drug is too lipophilic, it will not be absorbed well and 
therefore be unable to reach the cell3. This characteristic is known as bioavailability and must be 
balanced to properly administer a drug to a target cell3. Adding fluorine to a structure can help 
achieve the desired level. An important class of fluorine-containing drugs that have gained 
prominence is the selective serotonin reuptake inhibitors (SSRIs). Of the most widely used drugs 
in this class, only one, sertraline, does not contain a fluorine atom, and it has the shortest half-life 
of the SSRIs and is absorbed the most slowly3. These properties may all be attributed to the lack 
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of fluorine, demonstrating just how useful the addition of fluorine is in controlling drug 
metabolism3. 
  Integrating fluorine into compounds also provides improved metabolic stability against 
oxidation enzymes in the liver3. Drugs administered orally are transported immediately from the 
small intestine to the liver where they are oxidized, but substitution of hydrogen for fluorine in 
compounds prevents the degradation of the drug via oxidative attack3. This is due to the strength 
of the carbon-fluorine bond, which allows for resistance against enzyme degradation3. Thus, the 
drug’s structure is preserved, increasing its half-life. The incorporation of fluorine into a 
compound can also prevent toxic or “non-productive” metabolism, making the drug safer3.   
   Due to these characteristics, fluorine is playing an increasingly important role in drug 
discovery. According to a 2015 survey, several drugs containing fluorine were among the most-
prescribed and/or profitable in the pharmaceutical market4. In fact, four of the top ten best-selling 
name brand drugs in 2015, (Crestor, Sovaldi, Advair, Januvia) contained at least one fluorine 
atom5. These drugs, which made $19.6 billion in 2015, contain a wide array of functions5. 
Crestor is a member of the statin family, used in the treatment of high cholesterol5. Sovaldi is 
used to treat hepatitis C5. Advair is an oral inhaler used to treat asthma and pulmonary disease, 
and Januvia is an antidiabetic drug that makes more insulin available for the body to use5. This 
wide range of uses shows the diversity of fluorine in pharmaceuticals.  
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Figure 1: Examples of fluorine-containing pharmaceuticals4
Limitations in Drug Design 
Even though fluorine plays such an important role in the pharmaceutical industry, there 
are several restrictions in the synthesis of fluorinated drugs. Many of the conventional 
fluorination reactions developed in the early twentieth century are limited only to simple 
molecules, so fluorination of complex molecules at certain locations is challenging6. 
Additionally, only a few fluorinating enzymes have been found, making it very rare in nature6. 
Because of this, chemists are working to develop synthetic routes to integrate fluorine into 
organic compounds6. However, synthetic methods for fluorinating compounds also present 
challenges, one being that the reactivity of fluorine is limited by its electronegativity6. The 
electrons around fluorine are strongly attracted to its nucleus, making it unlikely for them to form 
Advair 
Januvia 
Sovaldi Crestor 
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a bond with another atom6. Fluorine is also able to form strong hydrogen bonds, making it a 
weak nucleophile in the presence of hydrogen donors6. This makes it difficult to perform 
nucleophilic substitution reactions that replace hydrogen atoms with fluorine6. Fluoride is a 
better nucleophile when hydrogen-bond donors are excluded, but it is also basic, which can lead 
to undesired side reactions6. 
Section 1.2 – Isoxazoles in Medicinal Chemistry 
Isoxazoles are five-membered aromatic heterocycles with oxygen and nitrogen in the 1, 2 
positions7. They exhibit a large range of biological properties, including anti-cancer, anti-
convulsant, anti-Alzheimer, anti-diabetic, anti-viral, immune-modulatory, and analgesic (Figure 
2)8. These beneficial properties have led to isoxazoles becoming the focus of many medicinal
chemistry studies in recent years7. Isoxazole rings are present in a large number of 
pharmaceuticals, contributing to their biological activity due to the presence of its two 
electronegative atoms in a 1,2-relationship9. These atoms are able to engage in hydrogen bond 
donor/acceptor interactions with a variety of compounds unavailable to other ring structures, 
allowing the compound to display useful properties it would otherwise not possess9.  
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Figure 2: Examples of drugs containing isoxazole rings8 
 
Isoxazole Synthesis Methods 
 Several synthetic routes have been developed to construct isoxazole core structures. 
Examples include the [3 + 2] cycloaddition of alkynes/alkenes and nitrile oxides, intermolecular 
cyclization of α,β-unsaturated oximes, intermolecular cyclization of oximes with C-C 
double/triple bonds, and palladium-catalyzed reactions9. However, synthetic routes for 
fluorinated isoxazoles in particular are limited due to the difficulty caused by direct fluorination9. 
Reported synthetic routes often have poor yields and require harsh conditions10. The past 
representative route for the synthesis of fluoroisoxazoles involves the condensation of 2-fluoro-
1,2-diketone and hydroxylamine·HCl in EtOH/H2SO410. This route suffers from a poor yield and 
needs strongly acidic conditions10. Another route involves electrophilic fluorinating reagents, but 
the reaction is sluggish and requires ever harsher reaction conditions such as reflux in 
sulfolane10. This also results in low yields (28-39%) and trifluorinated byproducts10. These 
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pathways are shown in Figure 3. Due to the importance of fluorine and isoxazoles in 
pharmaceuticals, the need for a practical synthetic route of fluorinated isoxazoles is crucial. 
Figure 3: Reaction schemes for the synthesis of fluorinated isoxazoles10
i) 
ii)
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Chapter 2: Results and Discussion 
Section 2.1 – Hypothesis 
A gold-catalyzed cyclization-fluorination of O-methyl oximes to form fluorinated 
isoxazoles was reported in 2014 (Figure 4)10. Our lab hoped to discover an alternative route to 
produce fluorinated isoxazoles using a less expensive catalyst. 
Figure 4: Synthesis of 4-fluoroisoxazole via gold catalysis10
A silver-catalyzed synthesis of disubstituted isoxazoles via cyclization of alkynyl oxime 
ethers was recently reported11. Using this report, our lab previously hypothesized that silver(I) is 
able to activate the carbon-carbon triple bond found in oxime and cyclize to form an oxonium 
intermediate. When an electrophilic fluorinating source is added, the silver is eliminated, and 
fluorinated isoxazole is produced, as shown in Figure 4. For preliminary investigation, our lab 
chose (Z)-1-phenyl-3-(p-tolyl)prop-2-yn-1-one O-methyl oxime as a model substrate to carry out 
the cyclization reaction with. Preliminary results showed that carrying out the reaction in the 
presence of AgBF4 and Py.Cl2.F, stirring in MeCN in an inert atmosphere at 80 ºC for 48 hours 
led to decent yields of fluorinated isoxazole and a protonated isoxazole byproduct. We decided 
to use this preliminary data to optimize the reaction.  
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Figure 5: Silver-catalyzed synthesis of 4-fluoro disubstituted isoxazole 
Section 2.2 – Ynone Synthesis 
The Roy lab previously found that the cyclization reaction of the model substrate (Z)-1-
phenyl-3-(p-tolyl)prop-2-yn-1-one O-methyl oxime could produce a fluorinated isoxazole. 
However, a protonated isoxazole was also formed as a by-product. The goal of this experiment 
was to produce the oxime substrate previously used and then further optimize the cyclization 
reaction previously reported. However, an ynone starting material had to first be prepared, from 
which the oxime substrate could be formed. 
The first reaction involved the preparation of an ynone via palladium/copper catalyzed 
Sonogashira coupling of a terminal acetylene and acid chloride. The palladium-catalyzed 
Sonogashira reaction is a very useful method for creating new bonds starting from alkynyl 
halides and terminal alkynes and is widely used for synthesizing acetylenic ketones, such as 
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ynones, that act as building blocks for the synthesis of pharmaceuticals and other organic 
materials12. Because acyl chlorides oxidatively add to Pd(0) species, forming a Pd(II) 
intermediate, it is possible to intercept this species with a nucleophile, as shown in Figure 413.   
 
 
 
Figure 6: Sonogashira coupling reaction 
 
 In Sonogashira reactions terminal alkynes are activated as nucleophiles using a CuI 
catalyst under basic conditions12. A large range of functional groups on the acetylene are 
compatible with this reaction12. Alkyl, ester, and protected amino groups in particular give 
isolated products in high yields12.   
 Three separate reactions were run at room temperature for 24 hours. The resulting 
product was 1-phenyl-3-(p-tolyl)prop-2-yn-1-one, and the obtained product was a dark brown 
solid. The results are shown in Table 2. 
 
 
Figure 7: Ynone Synthesis Scheme 
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Table 2: Ynone synthesis results 
Entry Temperature Time (h) Yield (%) 
1 rt 24 77.3 
2 rt 24 36.72 
3 rt 24 37.10 
Section 2.3 – Oxime Synthesis 
The second step of the project involved preparation of the O-methyl oxime substrate by 
stirring the prepared ynone in the presence of methoxylamine hydrochloride, pyridine, and 
Na2SO4 at room temperature, with methanol acting as the solvent.  
Three separate reactions were run at room temperature for 26 hours. The resulting 
product was (Z)-1-phenyl-3-(p-tolyl)prop-2-yn-1-one O-methyl oxime, and the obtained product 
was a yellow oil. The results are shown in Table 3. 
Figure 8: Oxime Synthesis Scheme 
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 Table 3: Oxime synthesis results  
Entry Temperature Time (h) Yield (%) 
1 rt 26 16.9 
2 rt 26 15.7 
3 rt 26 39.31 
 
 
Section 2.3 – Optimization  
 The cyclization reaction with oxime was previously carried out in the presence of 1 
equivalent of AgBF4 and Py.Cl2.F, while stirring in MeCN at 80 ºC for 48 hours. Results showed 
that this produced a mixture of fluorinated isoxazole and protonated isoxazole in 45% and 32% 
respectively. The goal of this experiment was to repeat these conditions and then further 
optimize the synthesis reaction with other catalysts.  
 In this experiment, the standard reaction conditions included 1 equivalent of oxime, 2 
equivalents of Py.Cl2.F. The silver catalyst equivalence varied however. The results are shown in 
Table 4. 
 
Figure 9: Synthesis of 4-fluoro disubstituted isoxazole 
 
 
 13 
Table 4: Optimization for silver catalyzed synthesis of 4-fluoro isoxazole 
Entry Temperature (ºC) Ag Catalyst, 
equiv. 
Solvent Yield, 1 (%)[a] Yield, 2 (%) 
1 80 AgBF4, 1 MeCN n.o. n.o.
1 80 AgBF4, 2 MeCN n.o. n.o.
[a] isolated yield n.o.: not observed
Section 2.5 – Conclusion 
Neither our desired product nor its protonated by-product were observed in either of the 
optimization reactions. In previous reactions done in our lab, these reactions were performed in 
an inert atmosphere. However, we were not able to replicate these conditions due to broken 
equipment, which may have affected the results.  
We were in the process of determining the cause of these results when our work was cut 
short due to the COVID-19 pandemic. However, the optimization of this reaction will be 
continued in our laboratory using previous results from the silver-catalyzed cyclization-
fluorination of (Z)-1-phenyl-3-(p-tolyl)prop-2-yn-1-one O-methyl oxime to yield fluorinated 
isoxazole.    
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Supplemental Information 
(1) A reaction tube with a magnetic stir bar containing 24.6 mg copper(I) iodide (0.10
equiv.) and 45.4 mg bis(triphenylphosphine)palladium(II) chloride (0.05 equiv.) was
degassed and back filled with argon three times. 363 mg benzoyl chloride (2 equiv.) was
dissolved in 2 mL THF and added to the mixture. Then 150 mg 1-ethynyl-4-
methylbenzene (1 equiv.) was dissolved in 0.54 mL Et3N (3 equiv.), added dropwise. 1.5
mL THF was then added to the reaction vial. The vial was then stirred at 25 ºC for 24
hours. After completion of reaction and confirmation by TLC chromatography, the
mixture was quenched with water and extracted with ethyl acetate in a separatory funnel.
After the layers were separated, the organic phase was dried over anhydrous Na2SO4 and
evaporated on a rotary evaporator to give the crude product, which was purified by flash
chromatography on silica gel using hexane/ethyl acetate (20:1) as the eluent. The
product was a dark brown solid. 1H NMR (400 MHz, CDCl3) δ 8.23 (m, J = 7.7 Hz,
2H), 7.61 (dd, J = 15.2 Hz, 3H), 7.52 (t, J = 7.7 Hz, 2H), 7.24 (d, J = 8.0 Hz, 2H), 2.41
(s, 3H).
(2) A reaction tube with a magnetic stir bar containing 164 mg copper(I) iodide (0.10
equiv.) and 302.1 mg bis(triphenylphosphine)palladium(II) chloride (0.05 equiv.) was
degassed and back filled with argon three times. 2.420 g benzoyl chloride (2 equiv.) was
dissolved in 12 mL THF and added to the mixture. Then 1000 mg 1-ethynyl-4-
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methylbenzene (1 equiv.) was dissolved in 3.6 mL Et3N (3 equiv.), added dropwise. 11 
mL THF was then added to the reaction vial. The vial was then stirred at 25 ºC for 24 
hours. After completion of reaction and confirmation by TLC chromatography, the 
mixture was quenched with water and extracted with ethyl acetate in a separatory funnel. 
After the layers were separated, the organic phase was dried over anhydrous Na2SO4 and 
evaporated on a rotary evaporator to give the crude product, which was purified by flash 
chromatography on silica gel using hexane/ethyl acetate (20:1) as the eluent. The 
product was a dark brown solid. 1H NMR (400 MHz, CDCl3) δ 8.26-8.23 (m, 2H), 7.63 
(dd, J = 11.6 Hz, 3H), 7.54 (t, J = 7.6 Hz, 2H), 7.26 (d, J = 7.9 Hz, 2H), 2.44 (s, 3H). 
(3) A reaction tube with a magnetic stir bar containing 327.9 mg copper(I) iodide (0.10
equiv.) and 604.3 mg bis(triphenylphosphine)palladium(II) chloride (0.05 equiv.) was
degassed and back filled with argon three times. 4.841 g benzoyl chloride (2 equiv.) was
dissolved in 12 mL THF and added to the mixture. Then 2.0 g 1-ethynyl-4-
methylbenzene (1 equiv.) was dissolved in 7.2 mL Et3N (3 equiv.), added dropwise. 11
mL THF was then added to the reaction vial. The vial was then stirred at 25 ºC for 24
hours. After completion of reaction and confirmation by TLC chromatography, the
mixture was quenched with water and extracted with ethyl acetate in a separatory funnel.
After the layers were separated, the organic phase was dried over anhydrous Na2SO4 and
evaporated on a rotary evaporator to give the crude product, which was purified by flash
chromatography on silica gel using hexane/ethyl acetate (20:1) as the eluent. The
product was a dark brown solid. 1H NMR (400 MHz, CDCl3) δ 8.28-8.23 (m, 2H), 7.68-
7.6 (dd, 3H), 7.54 (t, J = 7.6 Hz, 2H), 7.26 (d, J = 7.9 Hz, 2H), 2.44 (s, 3H).
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(4) In a reaction vial with a magnetic stir bar, 100 mg 1-phenyl-3-(p-tolyl)prop-2-yn-1-one
(1 equiv.), 75.8 mg O-methylhydroxylamine hydrochloride (2 equiv.), and 129 mg
sodium sulfate (2 equiv.) were dissolved in .5 mL MeOH. 0.073 mL pyridine (2 equiv.)
was then added via syringe dropwise over 20 minutes, and the mixture was stirred at
room temp for 26 hours. After completion of the reaction and confirmation by TLC
chromatography, the mixture was quenched with water and extracted with ethyl acetate
in a separatory funnel. The organic layer was then dried over anhydrous Na2SO4 and
evaporated on a rotary evaporator to give the crude product, which was purified by flash
chromatography on silica gel using hexane/ethyl acetate (20:1) as the eluent. The
obtained product was a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.93 (m, J = 6.7, 3.0
Hz, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.43-7.38 (dd, 3H), 7.20 (d, J = 7.8 Hz, 2H), 4.15 (s,
3H), 2.39 (s, 3H).
(5) In a reaction vial with a magnetic stir bar, 500 mg 1-phenyl-3-(p-tolyl)prop-2-yn-1-one
(1 equiv.), 379 mg O-methylhydroxylamine hydrochloride (2 equiv.), and 645 mg
sodium sulfate (2 equiv.) were dissolved in .5 mL MeOH. 0.731 mL pyridine (4 equiv.)
was then added via syringe dropwise over 20 minutes, and the mixture was stirred at
room temp for 26 hours. After completion of the reaction and confirmation by TLC
chromatography, the mixture was quenched with water and extracted with ethyl acetate
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in a separatory funnel. The organic layer was then dried over anhydrous Na2SO4 and 
evaporated on a rotary evaporator to give the crude product, which was purified by flash 
chromatography on silica gel using hexane/ethyl acetate (20:1) as the eluent. The 
obtained product was a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.92 (m, J = 6.6, 3.0 
Hz, 2H), 7.52 (d, J = 8.0 Hz, 2H), 7.42-7.39 (dd, 3H), 7.19 (d, J = 7.9 Hz, 2H), 4.14 (s, 
3H), 2.39 (s, 3H). 
(6) In a reaction vial with a magnetic stir bar, 1000 mg 1-phenyl-3-(p-tolyl)prop-2-yn-1-one
(1 equiv.), 758.3 mg O-methylhydroxylamine hydrochloride (2 equiv.), and 1.290 g
sodium sulfate (2 equiv.) were dissolved in 10 mL MeOH. 1.46 mL pyridine (4 equiv.)
was then added via syringe dropwise over 20 minutes, and the mixture was stirred at
room temp for 26 hours. After completion of the reaction and confirmation by TLC
chromatography, the mixture was quenched with water and extracted with ethyl acetate
in a separatory funnel. The organic layer was then dried over anhydrous Na2SO4 and
evaporated on a rotary evaporator to give the crude product, which was purified by flash
chromatography on silica gel using hexane/ethyl acetate (20:1) as the eluent. The
obtained product was a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.95-7.91 (m, 2H),
7.54 (d, J = 8.1 Hz, 2H), 7.42 (dd, J = 6.7, 2.8 Hz, 3H), 7.21 (d, J = 7.9 Hz, 2H), 4.16 (s,
3H), 2.41 (s, 3H).
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(7) A reaction vial with a magnetic stirring rod was charged with 30 mg (Z)-1-phenyl-3-(p-
tolyl)prop-2-yn-1-one O-methyl oxime (1 equiv.) and 61 mg 2,6-dichloro-1-
fluoropyridin-1-ium tetrafluoroborate (2 equiv.). The reaction vial was then degassed
and back-filled with argon three times. 23 mg (Tetrafluoro-l5-boraneyl)silver (1 equiv.)
was then added. After that, 0.3 mL MeCN was added via syringe. The reaction vial was
then stirred at 80 ºC for 48 hours. 19F NMR (377 MHz, CDCl3) δ -113.09- -113.18 (m).
(8) A reaction vial with a magnetic stirring rod was charged with 20 mg (Z)-1-phenyl-3-(p-
tolyl)prop-2-yn-1-one O-methyl oxime (1 equiv.) and 41 mg 2,6-dichloro-1-
fluoropyridin-1-ium tetrafluoroborate (2 equiv.). The reaction vial was then degassed
and back-filled with argon three times. 31 mg (Tetrafluoro-l5-boraneyl)silver  (2 equiv.)
was then added. After that, 0.3 mL MeCN was added via syringe. The reaction vial was
then stirred at 80 ºC for 48 hours. 19F NMR (377 MHz, CDCl3) δ -113.06 (d, J = 8.8
Hz), -148.94, -149.31 (d, J = 23.0 Hz), -149.51, -151.95, -178.34.
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